This database contains 523 studies, archived under the term: "Alzheimer’s Disease"
Click here to filter this large number of results.
Rivastigmine patch ameliorates depression in mild AD: Preliminary evidence from a 6-month open-label observational study
Spalletta, Gianfranco,
Gianni, Walter,
Giubilei, Franco,
Casini, Anna R.,
Sancesario, Giuseppe,
Caltagirone, Carlo,
Cravello, Luca
Here we investigated the effect of the rivastigmine patch alone on depression in 50 mild Alzheimer’s Disease (AD) patients with comorbid major depressive episode (MDE). First diagnosis acetyl-cholinesterase inhibitor and psychoactive drug-free outpatients (n = 50) were recruited in memory clinics and reassessed after 3 and 6 months. Global cognitive functioning, depressive symptoms and MDE […]
Angiotensin-converting enzyme inhibitors and Alzheimer’s disease progression in older adults: results from the Réseau sur la Maladie d’Alzheimer Français cohort
Soto, Maria E.,
Abellan van Kan, Gabor,
Nourhashemi, Fati,
Gillette-Guyonnet, Sophie,
Cesari, Matteo,
Cantet, Christelle,
Rolland, Yves,
Vellas, Bruno
Objectives: To assess whether angiotensin-converting enzyme inhibitor (ACE-I) treatment is associated with less cognitive decline in older adults with Alzheimer’s disease (AD) than in those using other hypertensive or no drugs.; Design: Four-year prospective multicenter cohort study with a biannual assessment.; Setting: Memory clinics from 16 university hospitals in France.; Participants: Community-dwelling older adults with […]
Cognitive subdomain responses to galantamine in Alzheimer’s disease
Song, Jihye,
Ahn, Inn Sook,
Kang, Hyo Shin,
Myung, Woojae,
Lee, Yujin,
Woo, Sook-young,
Ku, Hyoung Mo,
Hwang, Tae-Young,
Carroll, Bernard J.,
Kim, Doh Kwan
We investigated the effects of galantamine on cognitive subdomains in Alzheimer’s disease (AD). Sixty-six patients with mild-to-moderate AD received open-label galantamine for 52 weeks. Cognitive function was measured using the Korean version of the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog-K). Response to galantamine was defined as “improvement or no deterioration” on the total scores of […]
Effect of the timing of acetylcholinesterase inhibitor ingestion on sleep
Many patients with Alzheimer’s disease experience sleep disturbances, and donepezil is usually prescribed for night-time administration. However, increased acetylcholine is associated with cortical arousal. We evaluated whether subjective sleep quality differed according to the timing of medication administration. Ninety-two patients with mild to moderate Alzheimer’s disease who had taken donepezil at night (n=54) or galantamine […]
Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer’s disease
Solé-Padullés, Cristina,
Bartrés-Faz, David,
Lladó, Albert,
Bosch, Beatriz,
Peña-Gómez, Cleofé,
Castellví, Magdalena,
Rami, Lorena,
Bargalló, Nuria,
Sánchez-Valle, Raquel,
Molinuevo, José Luis
Previous studies with functional magnetic resonance imaging (fMRI) demonstrated a differential brain activity and connectivity after treatment with donepezil in Alzheimer’s disease (AD) when compared to healthy elders. Importantly however, there are no available studies where the placebo or control group included comparable AD patients relative to the treated groups. Fifteen patients recently diagnosed of […]
Cost analysis of early psychosocial intervention in Alzheimer’s disease
Søgaard, Rikke,
Sørensen, Jan,
Waldorff, Frans B.,
Eckermann, Ane,
Buss, Dorthe V.,
Waldemar, Gunhild
Background/aim: To investigate the impact of early psychosocial intervention aimed at patients with Alzheimer’s disease (AD) and their caregivers on resource use and costs from a societal perspective.; Methods: Dyads of patients and their primary caregiver were randomised to intervention (n = 163) or control (n = 167) and followed for 3 years. Health care […]
Physical activity reduces hippocampal atrophy in elders at genetic risk for Alzheimer’s disease
Smith, J. Carson,
Nielson, Kristy A.,
Woodard, John L.,
Seidenberg, Michael,
Durgerian, Sally,
Hazlett, Kathleen E.,
Figueroa, Christina M.,
Kandah, Cassandra C.,
Kay, Christina D.,
Matthews, Monica A.,
Rao, Stephen M.
We examined the impact of physical activity (PA) on longitudinal change in hippocampal volume in cognitively intact older adults at varying genetic risk for the sporadic form of Alzheimer’s disease (AD). Hippocampal volume was measured from structural magnetic resonance imaging (MRI) scans administered at baseline and at an 18-month follow-up in 97 healthy, cognitively intact […]
Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry
Skillbäck, Tobias,
Rosén, Christoffer,
Asztely, Fredrik,
Mattsson, Niklas,
Blennow, Kaj,
Zetterberg, Henrik
Importance: Identifying a clinical distinction between the invariably lethal prion disease Creutzfeldt-Jakob disease (CJD) and nonprion rapidly progressive dementias is important and sometimes difficult; thus, reliable tools for diagnosis are in great demand.; Objective: To test the diagnostic performance of dementia cerebrospinal fluid (CSF) biomarkers total tau (T-tau), phosphorylated tau (P-tau), and the T-tau to […]
Alzheimer’s disease (AD) and executive dysfunction. A case-control study on the significance of frontal white matter changes detected by diffusion tensor imaging (DTI)
Sjöbeck, Martin,
Elfgren, Christina,
Larsson, Elna-Marie,
Brockstedt, Sara,
Lätt, Jimmy,
Englund, Elisabet,
Passant, Ulla
White matter (WM) changes are frequently seen on structural imaging in AD but the clinical relevance of these changes is uncertain. Frontal WM pathology is often observed upon neuropathological examination in AD. Since frontal cortical/sub-cortical pathology is known to relate to executive dysfunction, the aim was to elucidate if frontal WM changes in AD correlated […]